Journal of Clinical and Cellular Immunology
Open Access
ISSN: 2155-9899
+44 1223 790975
ISSN: 2155-9899
+44 1223 790975
Jean-François Fonteneau
INSERM UMR892, CNRS UMR6299, Institut de Recherche Thérapeutique de l’Université de Nantes,
8 quai Moncousu, BP70721, 44007 Nantes, Cedex1
France
Review Article
Induction of Immunogenic Tumor Cell Death by Attenuated Oncolytic Measles Virus
Author(s): Carole Achard, Nicolas Boisgerault, Tiphaine Delaunay, Frédéric Tangy, Marc Grégoire and Jean-François FonteneauCarole Achard, Nicolas Boisgerault, Tiphaine Delaunay, Frédéric Tangy, Marc Grégoire and Jean-François Fonteneau
Antitumor virotherapy is a developing approach to treat cancer with oncolytic viruses, namely replicative viruses that exclusively or preferentially infect and kill tumor cells. Attenuated strains of Measles Virus (MV) are now being used as oncolytic viruses in clinical trials to treat several types of cancer. The efficacy of oncolytic viruses is mainly due to their capacity to infect and kill tumor cells, but it has also been demonstrated that their capacity to induce immunogenic cell death can activate an antitumor immune response. In this review, we describe the oncolytic capacity of MV and the concept of Immunogenic Cell Death (ICD). We then review how MV induces immunogenic cell death, which can be beneficial for cancer treatment.
.. View More»
DOI:
10.4172/2155-9899.1000291